iShares MSCI World ETF Draws Cash Despite Mounting Headwinds

Investors pour $500M into iShares MSCI World ETF despite a 0.24% fee, looming drug tariffs hitting its healthcare sector, and a major index overhaul ahead with SpaceX's potential listing.

Investors are pouring money into the iShares MSCI World ETF, even as a combination of competitive, political, and structural challenges gathers force. The fund attracted nearly half a billion US dollars in just five trading days, lifting its assets under management to approximately $7.5 billion. This demand persists despite a glaring fee disadvantage and looming portfolio risks.

The competitive landscape is intensifying. On April 1, Invesco slashed the management fee on its comparable ETF to 0.05%. BlackRock’s iShares product, with a total expense ratio of 0.24%, now charges almost five times that amount. Analysts at Morningstar have highlighted this cost disadvantage relative to offerings from rivals like UBS and BNP Paribas. Yet, major institutions continue to buy. The Royal Bank of Canada recently increased its stake by 17.5%, suggesting the fund's deep liquidity and brand recognition outweigh cost concerns for some. Trading volume exceeding 650,000 shares at the start of the month underscores this sustained interest.

Political headwinds are building within the portfolio itself. In early April, President Trump signed an executive order imposing tariffs on patented pharmaceuticals. Starting in late July 2026, imports from companies without US pricing agreements will face a 100% duty, directly impacting the ETF’s healthcare sector. The fund’s substantial 26% technology weighting is also vulnerable. Holdings in Nvidia, Apple, and Microsoft alone account for 13.6% of the portfolio. Strategists warn the new tariffs could dampen global growth and add roughly 0.5 percentage points to inflation, squeezing the profit margins of these core holdings.

Looking ahead, the ETF faces a period of profound structural change. The most dramatic potential shift stems from SpaceX’s confidential filing for a Nasdaq listing in June 2026. With a targeted valuation of up to $1.75 trillion, its inclusion in the MSCI World index would trigger billions in passive capital flows, significantly boosting the index’s US weighting and its exposure to software and aerospace.

This comes alongside a scheduled overhaul of the index’s methodology. In May 2026, MSCI will revise its calculation for company free floats. This technical change is expected to drive a marked increase in portfolio turnover, as a rebalancing in March was deliberately kept minimal to prepare for it. Should SpaceX join under these new rules, the concentration in US equities and specific sectors would be further amplified.

The next key date for shareholders is the ex-dividend date on June 15, 2026, following a period where the fund’s dividend growth exceeded 20% year-over-year. Capital flows during the second quarter will serve as a critical gauge of how institutional investors are weighing the combination of higher fees, new pharmaceutical tariffs, and the impending index restructuring.